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Abstract
Background: Cancer centers are pressured to deliver high-quality services that can be measured and improved,
which has led to an increase of assessments in many countries. A critical area of quality improvement is to improve
patient outcome. An overview of existing assessments can help stakeholders (e.g., healthcare professionals,
managers and policy makers) improve the quality of cancer research and care and lead to patient benefits.
This paper presents key aspects of assessments undertaken by European cancer centers, such as: are assessments
mandatory or voluntary? Do they focus on evaluating research, care or both? And are they international or national?
Methods: A survey was sent to 33 cancer centers in 28 European Union member states. Participants were asked to
score the specifics for each assessment that they listed.
Results: Based on the responses from 19 cancer centers from 18 member states, we found 109 assessments. The
numbers have steadily increased from 1990’s till 2015. Although, a majority of assessments are on patient-care aspects
(n = 45), it is unclear how many of those include assessing patient benefits. Only few assessments cover basic research.
There is an increasing trend towards mixed assessments (i.e., combining research and patient-care aspects)
Conclusions: The need for assessments in cancer centers is increasing. To improve efforts in the quality of research
and patient care and to prevent new assessments that “reinvent the wheel”, it is advised to start comparative research
into the assessments that are likely to bring patient benefits and improve patient outcome. Do assessments provide
consistent and reliable information that create added value for all key stakeholders?
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Background
Cancer Centers (CCs) in Europe, are located in complex
organizational and regulatory environments and are in-
creasingly under pressure to deliver high-quality services
and be transparent about it [1]. As a consequence of this,
there is an increasing emphasis on quality and safety im-
provement initiatives [2]. Patients and payers increasingly
demand proof of guaranteed safety and quality of services.
Cancer care activities lead to a steadily growing financial
claim on national and regional health systems leading to
concerns on sustainability and value for money, especially
at a time of austerity measures and deficits in public bud-
gets [3, 4]. This has led to additional need for transparency
on quality matters and performance issues [5].
Determining what is quality and safety of care is com-
plex as it can reflect the combined perspectives of policy
makers, purchasers, payers, healthcare professionals, re-
searchers and patients [6]. The complexity of healthcare
systems and the unpredictable nature of health care adds
to this difficulty [7]. Setting and applying clear perform-
ance standards through regulatory mechanisms, such as
licensing, certification, and accreditation, is crucial to
ensure patient safety [8].
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CCs go through several assessments on their perform-
ance and quality, assessments being defined as: “A sys-
tem for evaluating performance, as in the delivery of
services or the quality of products provided to con-
sumers, customers, or patients” [9]. Its nomenclature ex-
tends to accreditation, certification, performance review,
(performance) evaluation and others. This study uses the
term assessments as it includes all of the above men-
tioned terms. So far an overview of the assessments on a
European level does not exist. A recent study among
Canadian Oncologists by Lim et al. [10] shows that one
of the reasons for them not participating in this type of
quality improvement initiatives is the lack of knowledge
about on-going initiatives. This example shows the rele-
vance of obtaining an overview of assessments.
This article presents key findings from a survey that was
conducted with CCs in the European Union. The goal was
to obtain an overview of existing assessments in terms of
whether they are: mandatory or voluntary; focused on
evaluating research or patient care or both; regional,
national and/or international. An example from the
Netherlands [11] shows that hospitals spend between 40.1
to 82.3 million Euros on quality assessments in 2014. This
study showed that much of the information gathered
through these assessments is, however, recorded twice, in-
efficiently and is accompanied by bureaucracy [11]. Unfor-
tunately there is limited evidence on the added value of
these (organizational) assessments for patient care or pa-
tient outcomes, primarily due to methodological issues re-
lated to limited insight into the mechanisms through
which these exert their effects. Though very relevant, that
is not the object of this overview.
The rationale for this study was originally to provide
input for the BENCH-CAN project [12]. The BENCH-
CAN project [12] aims at benchmarking comprehensive
cancer and yield best practice examples at eight Euro-
pean CCs in order to contribute to improvement of
multidisciplinary patient treatment. One of the objec-
tives of the BENCH-CAN project is: To collect, compare
and align, by consensus formation, the standards, rec-
ommendations and accreditation criteria of comprehen-
sive cancer care adopted in selected European countries
representatives of different geographic areas (North-
Western Europe; Southern Europe; Central-Eastern Eur-
ope). Because of the potential to inform decision makers
about existing assessments so that they can take some
steps towards regulating these as well as minimizing the
related bureaucracy, it was decided to expand the study
to other CCs than just the BENCH-CAN pilot sites..
Organizations conducting these assessments and (also
non EU) CCs can gain better understanding of what
type of assessments are currently undertaken in view of
growing interest in cooperation in international re-
search consortia [13, 14].
The context of European cancer centers
Assessments are contextual, and so, first there is a need
to understand the type of health system in which the
CCs operate. Health systems in the EU can be described
in different ways. For this article, the typology developed
by Rothgang et al. [15] and Wendt et al. [16] was used,
which suggests four types of health systems: the Na-
tional Health Service (NHS), National Health Insurance
(NHI), Social Health Insurance (SHI) and the Etatist
Social Health Insurance (ESHI). Three dimensions
distinguish each of these systems: financing, service
provision, and regulation [17]. According to this classi-
fication scheme each dimension can be dominated by
state (government), societal (for example NGO’s, consult-
ancy agencies or research institutes), or private actors (see
Fig. 1). The US system has a mix of characteristics of those
systems; however, unique about the US system in the
world is the dominance of the private for profit actors in
all three dimensions over the public sector (state/govern-
ment and societal/ non-governmental) [18].
Methods
Survey
A survey (see Additional file 1) was sent initially to the
BENCH-CAN pilot sites. After the decision to expand the
study, the survey was sent to one cancer center in each of
the EU member states with the exception of Belgium, Austria
and the UK where 2 cancer centers were contacted. This
was due to the lack of response within the given time-frame
from the first contacted center. A second center was con-
tacted in each of these countries. In total the survey was sent
to 33 cancer centers in the 28 EU countries. Ethics commit-
tee approval was deemed irrelevant for this study. For some
member states, CCs could not be easily identified and so,
other organizations dealing with cancer care and/or research
were contacted. CCs were identified through the European
Society for Medical Oncology (ESMO) [19] and the Organ-
isation of European Cancer Institutes (OECI) [20]. The sur-
vey was addressed to the lead administrative person in each
institute. Participants were asked to describe several topics
for each assessment that they listed: (i) the name of the
assessment body (i.e., organization that performed the assess-
ment) (ii) whether the body was public or private; (iii) if the
assessment was mandatory or voluntary; (iv) the level (i.e., re-
gional/national/international) at which the assessment was
performed; (v) if the assessment focused on research, patient
care aspects or a mix of standards (vi) the frequency of the
assessment; (vii) if the assessment led to keeping/losing oper-
ating license and/or public funding and (viii) the year in
which the assessment was first performed.
Data management and inclusion/exclusion criteria
Among the 28 EU member states in which CCs were
asked to participate, data were received from 18 member
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states i.e., one cancer institution per member state
(64 %), with the exception of Italy (two cancer institu-
tions). Not all surveys were filled out correctly and some
were missing data. A follow up was done by e-mail or
phone with all respondents to clarify the answers. Two
researchers inspected the data and excluded the listed
assessments that did not fit the inclusion criteria. The
inclusion criteria for the assessments were: the assess-
ment had to assess cancer care, cancer research or a
combination of both. All assessments that did not fit
these criteria were excluded from the study. Eligible
assessments were divided into three categories: clinical/
patient care oriented assessments; research oriented
assessments; and assessments that are oriented at a com-
bination of care and research. Clinical/Patient care ori-
ented assessments focus on the care delivered by Cancer
Centers, Research oriented assessments focus solely on
research performed at Cancer Centers, while combin-
ation oriented assessments focus on a comprehensive as-
sessment of both the care delivered as the research
performed in the CC (only applicable in centers were
both activities are fully developed). A content analysis
was performed. This method enables a more objective
evaluation than comparing content based on the impres-
sions of a reader and simplifies the detection of trends.
This analysis was executed by converting the different
items of the survey (public or private; mandatory or vol-
untary; regional/national/international; focused on re-
search, patient care aspects or both; the frequency; if the
assessment led to keeping/losing operating license and/
or public funding and the year in which the assessment
was first performed) into variables in excel. By dividing
the data into the variables, a structured overview of as-
sessment characteristics was obtained. This overview en-
abled the researchers to investigate trends in
assessments and possible relationships between types of
assessment and health systems. Two researchers inde-
pendently examined the data to check for Inter Rater
Reliability. The analysis of findings includes only pro-
grams that completed the survey. Validity of the data
was verified by checking the assessment body in an on-
line search and by asking the participating CCs to
double check the data provided. The full list of included
assessments was circulated amongst the respondents for
final data validation.
Results
Nature and scope of assessments
Based on the responses, we found 109 known cancer re-
lated quality assessments in total in 19 EU member states
(see Additional file 2). The majority of the assessments
focus on patient-care aspects (n = 45), such as waiting and
throughput times, patient participation and patient satis-
faction followed by the mixed assessments that focus on
patient care as well as research aspects (n = 37). In those
mixed assessment especially organizational aspects of care
and research such as multidisciplinary harmonization /
integrated care and scientific interaction and integration
receive emphasis, whereas pure research oriented assess-
ments, which are the least in number (n = 27), are directed
towards research outcomes such as number of publica-
tions. The majority of patient care oriented assessments
are reported to be mandatory. Mixed assessments are
more voluntary.
Fig. 1 Overview of typology of health systems in the EU. * Malta and Latvia have mixed public/private service provision. ** Slovenia conflicts with
the logic of the RW typology as societal actors are in charge of regulation and financing, but service provision lies predominantly in the hands of
state actors. Slovenia is, however, gradually evolving into a SHI
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The majority of assessments (n = 62) is done at the
national level (performed by national government spon-
sored federal agencies or performed by national ‘bodies’
unaffiliated with governments but with assessment au-
thority), followed by 34 assessments that are known to
be operational at an international level (performed by
international assessment agencies). Some assessments
are implemented at a national level, but are also oper-
ational at an international level, these have been
counted as national. There are only a handful of re-
gional assessments (n = 9) such as in Estonia and in
Finland (see Table 1). Almost all mandatory assess-
ments are national and are mainly related to keeping li-
cense and/or receiving public funding. In contrast,
most voluntary assessments are international, and ra-
ther aim at quality improvement and are seldom dir-
ectly tied to licensing or funding.
Trend of assessments
Respondents were asked in which year the first assess-
ment for the assessments began (see Additional file 3).
For some this can be easily identified, but for a majority
it is difficult to date precisely. The graph in Fig. 2 shows
a cumulative presentation of the trends in the number
and types of assessments. It suggests that:
 The numbers of assessments have steadily increased
from the 1990’s till 2015.
 In over the past two decades, there has been most
increase in patient care assessments, followed by
the mixed assessments of patient care and research
aspects. The rise in pure research assessments has
been the least.
Discussion
Continuous growth of assessments in Europe and how it
compares to the US
The number of assessments in the EU has tripled since
2000. This shows that quality assessments in all its forms
is a growing industry. It is particularly interesting to note
a steady rise from 2000 to 2007, and especially following
the economic crisis (2007/2008) more assessments seem
to have cropped up. Whether this steep rise is related to
the need for more accountability during and post finan-
cial crunch situations is hard to say. Although the em-
phasis on mandatory assessments will remain for the
purpose of funding and licensing health services, volun-
tary assessments are equally gaining in popularity. In
fact, most of the new assessments are voluntary, how-
ever, this does not exclude the pressure on CCs to par-
ticipate in them. This shows that most assessments seem
to be in a transition, moving from a friendly tool of self-
assessment and development to a governing tool that
agencies use for various purposes.
Regarding CCs, in the US there are at least three main
assessments: The Joint Commission accreditation [21]
for healthcare organizations and programs as a whole;
The Commission on Cancer (CoC) of the American
College of Surgeons for the quality of cancer care deliv-
ery [22]; and The National Cancer Institute (NCI) desig-
nation [23] for assessing excellent multidisciplinary
translational cancer research programs, in which almost
all leading CCs in the US participate. Europe is gradually
moving towards common European assessment frame-
works in order to benchmark and improve cancer re-
search and patient care activities across the EU, but this
has not been as developed as it is in the United States. It
is with this intention that European Commission is allo-
cating more budgets for research and innovation (e.g.,
through specific funding programs such as Horizon2020)
[24] with the idea of improving EU competitiveness in
excellent science [25]. However, the challenges that arise
from health care being under national jurisdiction and
individual responsibility of each EU member state has
meant that only gradual steps towards harmonization of
EU assessments have been seen so far. As healthcare is a
major component of national economies (as a user of
public funds but also as an investment that generates
jobs, taxes and procurement opportunities for Small and
Medium Enterprises) within a monetary union, increas-
ing steps towards EU influence on these issues seems in-
evitable [26].
Table 1 Level of assessments per country
EU member state International National Regional
Austria - 6 -
Croatia - 1 -
Czech Republic 2 6 -
Denmark 1 - -
Estonia - 5 2
Finland 4 3 2
France 1 2 -
Germany - 3 -
Hungary 2 1 -
Ireland - 1 -
Italy 6 - 1
Lithuania 1 6 -
Netherlands 3 2 -
Poland - 4 2
Portugal 2 3 -
Slovenia 12 8 -
Spain 2 3 2
United Kingdom 2 8 -
TOTAL 38 62 9
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The link between health system type and nature and
scope of assessments
A link between the type of health system and the nature
of the assessments is visible only in some member states.
For example, in the United Kingdom where a National
Health Service is being used (regulation, financing and
provision by the state, see Fig. 1) a lot of mandatory,
national assessments can be found. The same goes for
Spain. In other countries that have an NHS model, e.g.,
Finland and Portugal assessments seem to be more
voluntary than mandatory. Within the National Health
Insurance system (regulation by the state) one would
again expect a lot of mandatory and national assess-
ments, but the opposite is the case in Italy, where a lot
of international voluntary assessments are performed
e.g., the Joint Accreditation Committee- International
Society for Cellular Therapy and European Society for
Blood and Marrow Transplantation (JACIE) [27] and
International Organization for Standardization (ISO)
[28] and the European accreditation by the Organization
of European Cancer Institutes (OECI) [20]. But these
initially voluntary assessments are sometimes mandatory
for either keeping license and/or are demanded by gov-
ernment to maintain a Comprehensive Cancer Center
status, such as in Italy. Hence, voluntary assessments
end up being mandatory at some level.
In the Social Health Insurance (SHI) type, societal ac-
tors dominate healthcare regulation and financing,
which is reflected in the assessments listed by the cen-
ters from Germany and Croatia e.g., in Germany ac-
creditation of cancer care is performed by the German
Cancer society [29] which is a societal actor dominated
by physicians. In most Central and Eastern European
countries that have an Etatist Social Health Insurance
system, there is a tendency for more mandatory national
assessments, while in the majority of Western Europe
and Nordic countries there is tendency to participate in
more voluntary international assessments. Only in few
member states, did we notice regional level assessments
e.g., Italy, Finland and Estonia. This can be partly ex-
plained by decentralization/devolution of powers to re-
gions in some EU member states [30]. Evidence suggests
that mandated external quality assessments are less ef-
fective than voluntary assessments because the effective-
ness of accreditation is dependent on its voluntary
nature, non-threatening process, and interactive process
with external reviewers as a means of effecting and
speeding up quality improvements [31].
Traditional view of assessments and shifting focus
Assessments focused on research performed by CCs (such
as LabQuality which checks the quality of Laboratories
and BASG/AGES that looks at the quality of clinical drug
trials) are still limited in Europe when compared to patient
care assessments. The NCI designation program [23] in
the US is one of the anchors of the nation’s cancer re-
search effort. In order to be designated, CCs must meet
specific criteria for: breadth and depth of basic cancer re-
search; clinical cancer research; prevention, control and
population/behavioral sciences research in cancer; and
strength of interaction among these three major research
areas. A European version of the NCI designation was not
found in our study.
One of the possible reasons why patient care assess-
ments (such as certain accreditations) are performed
more often than research focused assessments is that,
being an accredited center in cancer care could attract
patients [32]. Additionally, in some countries, accredit-
ation is being used as an extension of statutory licensing
for institutions [33]. Therefore, care assessments such as
accreditation seem of more direct importance than
assessing research. Another reason is that assessing im-
pact of research on healthcare outcomes is more difficult
than assessing care outcomes [34]. In research, metric-
Fig. 2 Trends in the number and types of assessments
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driven indicators such as impact factors are often criti-
cized [35] and consensus on value-based indicators is
still evolving e.g., how to define success in translational
research (bench to bedside and back) in terms of
practice-changing innovations [36]. The awareness that
alignment between research and clinical areas is essential
in successful translational research [37] can explain why
more mixed assessments are being introduced in the
EU. This is comparable to the SPORE [38]-the Special-
ized Programs of Research Excellence-a cornerstone of
National Cancer Institute’s efforts dedicated to capitalize
on research opportunities that have the potential to
change the current paradigm in the prevention, detec-
tion, diagnosis, and/or treatment of cancer. Given the
amount of funding that goes into research in the EU as
in the US [39], evaluating research becomes necessary.
More specifically, comparative research assessments are
needed to make evidence based decisions on most suit-
able therapies in clinical practice [40].
Transparency
A review of accreditation and quality systems by the
World Health Organization [41] shows that “the move
towards statutory and governmental endorsement is as-
sociated with freer access by the public to the standards,
processes and findings of accreditation”. Half of the as-
sessment bodies make the standards/indicators used for
the assessment available at little or no cost. One-third
also makes full reports of individual assessments publicly
available. However, several organizations are unwilling to
give away their standards and norm descriptions as this
serves also as a source of income and intellectual prop-
erty. Other difficulties are for example the fact that in
many EU member states, the assessment reports as well
as the program standards are in the local language. It
takes time, money and effort to accurately translate the
reports into English. This makes it hard to judge assess-
ments in terms of how each assessment can bring added
value to the different stakeholders [41]. The first step in
deciding the value of assessments is to make their out-
comes publicly available and accessible [42] although
this assumption has been challenged [43]. Next, public
consultation must occur with key stakeholders to decide
the parameters to assess the added value of assessments
[44]. Another issue related to this is also whether the
data, if made publicly available, are good enough to
actually promote quality improvement and helping con-
sumers make choices [6]. Evidence on whether the as-
sessments undergone by CCs actually provide added
value for patient care or patient outcomes is limited.
Although most assessments focus on patient care as-
pects, it is unknown whether patient outcomes are actu-
ally improved through these assessments [45]. Evidence
shows that for example patient safety can be improved if
a healthcare organization undergoes licensing, certifica-
tion and accreditation [7] but this is unknown for pa-
tient outcomes. Although there is no decisive evidence
on the direct impact on patient outcomes, there is some
indication that quality assessments such as accreditation
could contribute to health outcomes. This is the case if
these assessments strengthen interdisciplinary team ef-
fectiveness, communication, and enhanced use of indica-
tors leading to evidence-based decision making [6]. This
evidence is however limited and study designs are weak.
A study focusing on accreditation specifically shows that
a lot of information on the added value of assessments is
unknown and future research should focus on: deter-
mining the impact of accreditation on patient care and
outcomes; determining how best to research the validity,
impact and value of accreditation processes in health
care; determination of value for time and money; and
determining the reliability of accreditation surveys to
truly assess the quality of organizations [45].
Strengths and limitations
This study describes the type and number of assess-
ments at 19 cancer centers in 18 out of 28 member
states of the European Union. This is the first systematic
European attempt to gather data on assessments for can-
cer centers. The results were validated with study partic-
ipants by asking them not just to confirm the data for
their own cancer center but also giving them an oppor-
tunity to comment on assessments that were listed by
other cancer centers in Europe. This study gives suffi-
cient base data to start thinking about how to reduce the
burden of assessments for cancer centers and how to
make them more transparent and effective.
Content of these assessments (e.g., assessment reports,
outcomes) were not easy to access due to language bar-
riers (each cancer center has it in its local European
language and is not always translated in English) and/or
lack of publicly available information. The individuals
from cancer centers who provided the data were quality
managers (and/or research directors/senior executive
managers) who are usually responsible for organizing and
implementing assessments in their center, However, many
assessments are multidisciplinary in nature, involving a
wide range of staff, therefore future research should focus
on validating the responses beyond quality managers. Our
assumption is that non-responses may have been the re-
sult of not identifying or contacting the appropriate
people, rather than reluctance to provide data and/or that
formalized assessments do not exist in some member
states. Another limitation regarding the year in which the
assessment started is the fact that, first assessments may
be considered as pilot testing rather than becoming oper-
ational. It is therefore difficult in some cases to identify
the year in which the actual assessment started.
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Conclusion
There seem to be 109 assessments that CCs currently
undergo in 19 EU states and the numbers keep increasing.
Although there are benefits of assessments, more robust re-
search is needed to understand their value in terms of how
they improve patient quality and safety. CCs go through
frequent assessments, sometimes as often as more than
once a year, this can be very time consuming as well as ex-
pensive for those organizations. Rapid uptake of voluntary
assessments is associated with direct financial incentives
(such as linkage to core funding or reimbursement) and
government encouragement. However, decision makers
should regulate assessments to reduce unnecessary assess-
ments that do not bring benefits or added value, that are
bureaucratic, time-consuming and/or unaffordable by CCs.
This article shows that demand for assessments is increas-
ing and changing rapidly in terms of international assess-
ments as well as mixed assessments of cancer research and
care. Assessments must be transparent to bring credibility
and accountability among stakeholders. Given the import-
ance of quality of care, patient safety and outcome improve-
ment in cancer care, it would be desirable to evaluate the
impact of assessments in these areas. We recommend fu-
ture research to go deeper into understanding process and
outcome related issues; how much time does each assess-
ment take to prepare and implement, people and money
consumed, who are the peer-reviewers and what are their
backgrounds, how are standards developed and revised,
sources of income for assessment bodies, and last but not
least does the exercise meet its objectives?
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